Gastric Cancer最新文献

{"title":"Author response to: Comment on: \"Gastric equivalent of the 'Holy Plane' to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson's historic schema\".","authors":"Hisashi Shinohara, Yasunori Kurahashi, Yoshinori Ishida","doi":"10.1007/s10120-025-01656-0","DOIUrl":"https://doi.org/10.1007/s10120-025-01656-0","url":null,"abstract":"","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-sequential prediction of postoperative complications after gastric cancer surgery using machine learning: a multicenter cohort study.","authors":"Motonari Ri, Souya Nunobe, Tomonori Narita, Yasuyuki Seto, Yoshimasa Kawazoe, Kazuhiko Ohe, Lena Azuma, Nobuyoshi Takeshita","doi":"10.1007/s10120-025-01658-y","DOIUrl":"https://doi.org/10.1007/s10120-025-01658-y","url":null,"abstract":"<p><strong>Background: </strong>Although many studies have developed logistic regression models for predicting complications using preoperative and intraoperative data, none have applied comprehensive perioperative information with machine learning (ML) to enable time-sequential predictions.</p><p><strong>Methods: </strong>This study included patients undergoing gastric cancer surgery between 2013 and 2019 at two hospitals. Comprehensive perioperative data were collected. Four ML models were developed: the postoperative day (POD) 1 and POD 3 models predicted complications occurring from POD 2 and POD 4, while the 24-h and 8-h models predicted complications within the 24 and 8 h, respectively, after collection of the most recent biochemical data and vital signs. Model performance was assessed using the area under the receiver operating characteristic curve (AUC) with repeated validation for generalizability.</p><p><strong>Results: </strong>Among 4139 patients, 782 (18.9%) experienced complications (Clavien-Dindo grade ≥ II). The 8-h model achieved the highest AUC (0.737) for overall complications. The POD 3 model outperformed the POD 1 model, with AUCs exceeding 0.8 for pancreatic fistula (0.869) and intra-abdominal abscess (0.821). The 8-h and the 24-h model both achieved AUCs above 0.8 for specific infectious complications. The 8-h model demonstrated the following AUCs: 0.889 for pancreatic fistula, 0.842 for intra-abdominal abscess, 0.826 for pneumonia, and 0.824 for anastomotic leakage, surpassing all POD-based models. In each 8-h model, C-reactive protein, pulse rate, and intraoperative blood loss consistently emerged as significant variables.</p><p><strong>Conclusion: </strong>Hour-based ML models incorporating comprehensive perioperative data predict post-gastric cancer surgery complications with high accuracy and time-sequential capability, potentially aiding clinical decision-making and improving outcomes.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting yes-associated protein to overcome imatinib resistance in gastrointestinal stromal tumor drug-tolerant persister cells.","authors":"Takashi Yokouchi, Tsuyoshi Takahashi, Toshirou Nishida, Koji Tanaka, Yukinori Kurokawa, Kazuyoshi Yamamoto, Takuro Saito, Takaomi Hagi, Kota Momose, Kotaro Yamashita, Tomoki Makino, Kunihiko Kawai, Satoshi Serada, Minoru Fujimoto, Seiichi Hirota, Kiyokazu Nakajima, Tetsuji Naka, Hidetoshi Eguchi, Yuichiro Doki","doi":"10.1007/s10120-025-01657-z","DOIUrl":"https://doi.org/10.1007/s10120-025-01657-z","url":null,"abstract":"<p><strong>Background: </strong>The tyrosine kinase inhibitor (TKI) imatinib targets KIT and PDGFRA, offering significant therapeutic benefits in advanced gastrointestinal stromal tumors (GISTs). However, the high rate of recurrence following treatment discontinuation suggests that drug-tolerant persister cells (DTPs) may contribute to therapy resistance. Elucidating the mechanisms underlying DTP survival is critical for the development of curative strategies. This study aimed to investigate the role of yes-associated protein (YAP) in DTP survival and to evaluate the efficacy of combining imatinib with YAP inhibitors as a potential therapeutic approach.</p><p><strong>Methods: </strong>Imatinib-sensitive GIST cell lines were treated with imatinib to generate DTPs. YAP activity was assessed via western blotting, fluorescence immunostaining, and nuclear-cytoplasmic fractionation. Proliferation and apoptosis assays were conducted to evaluate sensitivity to YAP inhibitors, such as verteporfin. Xenograft mouse models were used to assess the efficacy of combination therapy with imatinib and verteporfin.</p><p><strong>Results: </strong>DTPs exhibited increased nuclear localization and activity of YAP, which was reversible upon imatinib withdrawal. YAP inhibitors reduced nuclear YAP levels and showed greater efficacy in DTPs than in parental cells. Combination therapy with imatinib and verteporfin significantly suppressed DTP proliferation and induced apoptosis in vitro. In xenograft models, the combination therapy delayed tumor regrowth after treatment cessation compared to imatinib monotherapy.</p><p><strong>Conclusions: </strong>YAP activity was elevated in GIST DTPs, and YAP inhibitors effectively suppressed this activity. The combination of imatinib and YAP inhibitors enhanced tumor growth suppression. These findings underscore the pivotal role of YAP in DTP survival and demonstrate the therapeutic potential of combining imatinib with YAP inhibitors.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.","authors":"Shulun Nie, Shuyi Song, Qian Xu, Xin Dai, Aina Liu, Meili Sun, Lei Cong, Jing Liang, Zimin Liu, Jing Lv, Zhen Li, Jinling Zhang, Fangli Cao, Linli Qu, Haiyan Liu, Lu Yue, Yi Zhai, Song Li, Lian Liu","doi":"10.1007/s10120-025-01655-1","DOIUrl":"https://doi.org/10.1007/s10120-025-01655-1","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) play a pivotal role in the treatment of advanced gastric cancer (GC). However, the biomarkers used to predict ICI efficacy are limited due to their reliance on single or static tumor characteristics. This study aims to develop a machine learning (ML) model that incorporates dynamic changes in clinlabomics data to optimize the predictive accuracy of ICI efficacy.</p><p><strong>Methods: </strong>This multicenter, retrospective study utilized nine ML to construct the model. Participants were further stratified into low-risk and high-risk groups based on the predicted efficacy of ICI. Kaplan-Meier survival curves and RNA-sequencing were used for differential analysis.</p><p><strong>Results: </strong>This study enrolled 377 patients with advanced GC who underwent first-line ICI treatment across eleven hospitals between January 2018 and May 2023. Among them, 220 patients from Qilu Hospital of Shandong University were selected for the development model. The remaining ten hospitals contributed to two external test cohorts. Ten dynamic clinlabomics features were identified. The XGBoost demonstrated optimal performance in predicting ICI response, achieving an AUC of 0.863 in the training cohort, and 0.790-0.842 in the validation and two external cohorts. Notably, the model exhibited strong predictive capabilities compared to single point-in-time and previously proposed model. In the subgroup analysis, the low-risk subtype demonstrated a significantly improved prognosis and exhibited characteristics of \"hot tumors\". A web tool was generated: https://ici-therapeutic-efficacy-predictor-ztwwfwek2uckbmhxlnsayq.streamlit.app/ .</p><p><strong>Conclusions: </strong>The dynamic clinlabomics model can effectively predict the ICI efficacy in advanced GC. The model was validated using multicenter data and provides new evidence to optimize treatment decisions.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data.","authors":"Li-Li Shen, Hua-Long Zheng, Zhi-Wei Zheng, Bin-Bin Xu, Zhen Xue, Jia-Lin, Qi-Yue Chen, Jian-Wei Xie, Ping Li, Chang-Ming Huang, Jian-Xian Lin, Chao-Hui Zheng","doi":"10.1007/s10120-025-01622-w","DOIUrl":"10.1007/s10120-025-01622-w","url":null,"abstract":"<p><strong>Background: </strong>Emerging studies suggest obesity may improve PD-1/PD-L1 inhibitor efficacy, correlating with prolonged survival, known as the 'obesity paradox'. However, the impact of this paradox and obesity-related chronic inflammation on immunotherapy for advanced gastric cancer (AGC) has not received sufficient research.</p><p><strong>Methods: </strong>Between January 2018 and December 2021, patients receiving neoadjuvant therapy were categorized into two groups: combined immunotherapy (ICIs, n = 173) and neoadjuvant chemotherapy (NAC, n = 126). Visceral (VATI) and subcutaneous adipose tissue index (SATI) were obtained from pre-treatment CT images. The systemic immune-inflammation index (SII) was calculated as platelet count multiplied by the neutrophil-to-lymphocyte ratio.</p><p><strong>Results: </strong>The median age of patients was 64 years (IQR 56-69), with 219 (73.2%) males and 80 (26.8%) females. In the ICIs group, the VATI-High group showed significantly higher 3-year overall survival (OS) (p = 0.010) and disease-free survival (DFS) (p = 0.029). Similar results were observed in the SATI analysis (p < 0.05). Conversely, OS (p = 0.040) and DFS (p = 0.039) were significantly lower in the SII-High group. Both VATI and SATI were independent protective factors for OS and DFS, but the effect disappeared after adjustment for SII. SII was associated with poorer OS and DFS, even after adjustment for VATI and SATI. No significant differences were observed in the analysis of the NAC group.</p><p><strong>Conclusions: </strong>Elevated adiposity indices (VATI/SATI) and low SII correlate with survival benefit in ICI-treated AGC patients, and importantly, this paradoxical survival benefit is dependent on SII status. In contrast, no such benefit is observed in chemotherapy-alone cohorts.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"911-923"},"PeriodicalIF":5.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN.","authors":"Patrícia Mesquita, Alexandre Coelho, Ana S Ribeiro, Luís F C Póvoas, Catarina de Oliveira, Nelson Leça, Sara Silva, Diana Ferreira, Diana Pádua, Ricardo Coelho, Carmen Jerónimo, Joana Paredes, Carlos Conde, Bruno Pereira, Raquel Almeida","doi":"10.1007/s10120-025-01620-y","DOIUrl":"10.1007/s10120-025-01620-y","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is the fourth most common cause of cancer-related mortality and the fifth most common cancer worldwide. Despite efforts, the identification of biomarkers and new therapeutic approaches for GC remains elusive. Recent studies have begun to reveal the role of N6-adenosine methylation (m⁶A) in the regulation of gene expression.</p><p><strong>Methods: </strong>The expression of the reader YT521-B homology domain-containing family 3 (YTHDF3) in GC was assessed in 331 patients using immunohistochemistry. GC cell lines depleted of YTHDF3 using CRISPR-Cas9 were evaluated for migration, metastasis, orientation of the mitotic spindle, and response to paclitaxel. The association between YTHDF3 and EZRIN (EZR) mRNA was shown using RNA sequencing, immunofluorescence, real-time PCR, and RNA immunoprecipitation. The single-base elongation- and ligation-based qPCR amplification (SELECT) method was used to map m⁶A in the EZR transcript.</p><p><strong>Results: </strong>YTHDF3 was significantly overexpressed in GC, and high levels of YTHDF3 were predictive of the response to chemotherapy. In GC cell lines, YTHDF3 was the most highly expressed reader protein. YTHDF3 depletion impaired cytoskeleton organization, cell migration and metastasis, and orientation of the mitotic spindle, leading to an increased response to paclitaxel. EZR was one of the downregulated targets in the YTHDF3 knockout cell models and was associated with the observed phenotype.</p><p><strong>Conclusion: </strong>YTHDF3 contributes to cell motility and response to paclitaxel in GC cell lines, at least in part through EZR regulation. The YTHDF3-EZR regulatory axis is a novel molecular player in GC, with clinical relevance and potential therapeutic utility.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"760-775"},"PeriodicalIF":5.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on:\"Gastric equivalent of the 'Holy Plane' to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson's historic schema,\" Gastric cancer, 2021 Jan 2, by Hisashi Shinohara et al.","authors":"Zhiping Huang, Wei Zhang","doi":"10.1007/s10120-025-01638-2","DOIUrl":"10.1007/s10120-025-01638-2","url":null,"abstract":"<p><p>Over the past three decades, the implementation of the complete mesocolic excision (CME)/total mesorectal excision (TME) technique in colorectal cancer surgery has significantly reduced local recurrence rates and improved tumor-related survival outcomes. However, due to the morphological complexities of the gastric mesentery and its presence is still controversy, the concept of mesogastric excision(MGE) has yet to gain widespread acceptance in gastric cancer surgery. Nowadays, surgeons have begun to identify a dissectible loose connective-tissue layer between the lymph nodes and landmark structures through magnified images obtained during laparoscopic or robotic gastrectomy. We agree with the authors that MGE serves as a standardized concept in gastric cancer surgery.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"1017-1019"},"PeriodicalIF":5.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.","authors":"Keiji Sugiyama, Sacheen Kumar, Asif Chaudry, Nikhil Patel, Pranav Patel, David Cunningham, Naureen Starling, Sheela Rao, Charlotte Fribbens, Ian Chau","doi":"10.1007/s10120-025-01643-5","DOIUrl":"10.1007/s10120-025-01643-5","url":null,"abstract":"<p><strong>Background: </strong>Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard of care for locally advanced oesophagogastric adenocarcinoma (LA-OGA) in Western countries. However, completing treatment is challenging for patients, particularly in the postoperative setting. This study investigated the impact of adjuvant chemotherapy (ACT) administration and treatment completion on survival outcomes in patients receiving FLOT.</p><p><strong>Methods: </strong>Charts of LA-OGA patients treated from 2017 to 2023 were retrospectively reviewed. Survival was analysed using Kaplan-Meier and restricted mean survival time (RMST) analyses, with propensity score matching (PSM) adjustments. Subgroup analyses were stratified by pathological nodal status and tumour regression grade (Mandard TRG). The primary endpoint was 3-year overall survival (OS).</p><p><strong>Results: </strong>The study included 233 patients, among whom 62.4% completed the full perioperative FLOT regimen and 21% did not receive ACT. After PSM adjustment, 3-year OS for patients who completed and those who did not complete perioperative therapy was 69% and 57%, respectively (p = 0.09). The 3-year OS was 81% and 52% for patients who did and did not receive ACT, respectively (p = 0.01). In multivariate analysis, completion of perioperative FLOT was independently associated with improved OS (p = 0.04). Survival improvement with ACT was observed in the ypN-positive subgroup but not in the ypN-negative subgroup.</p><p><strong>Conclusions: </strong>Perioperative FLOT administration is recommended as the standard of care for LA-OGA. The survival impact of ACT might be influenced by pathological lymph node metastasis.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"968-981"},"PeriodicalIF":5.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.","authors":"Daniel Lin, Wenying Quan, Marne Garretson, Viktor Chirikov, Clara Chen, Prianka Singh, Catherine Davis, Ryan Sugarman","doi":"10.1007/s10120-025-01634-6","DOIUrl":"10.1007/s10120-025-01634-6","url":null,"abstract":"<p><strong>Background: </strong>Nivolumab plus chemotherapy demonstrated clinically significant improvement in quality-adjusted survival versus chemotherapy alone as first-line treatment for advanced non-HER2-positive gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC) in the CheckMate 649 post-hoc quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis at 1-year minimum follow-up. We report Q-TWiST analysis results at 4-year minimum follow-up.</p><p><strong>Methods: </strong>Q-TWiST methodology was applied post-hoc to CheckMate 649 study data from all randomized patients, patients with PD-L1 combined positive score (CPS) ≥ 1, and patients with PD-L1 CPS ≥ 5. Relative Q-TWiST gains ≥ 10% were predefined as clinically important and ≥ 15% as clearly clinically important.</p><p><strong>Results: </strong>Among all randomized patients, patients with PD-L1 CPS ≥ 1, and patients with PD-L1 CPS ≥ 5, mean (95% CI) absolute Q-TWiST gains of 3.4 (1.8-5.1), 4.2 (2.4-6.1), and 5.4 (3.0-7.7) months with nivolumab plus chemotherapy versus chemotherapy were observed, respectively. These translated to clearly clinically important relative Q-TWiST gains of 20.5%, 26.1%, and 33.4% in each population; relative Q-TWiST gains benefit remained clearly clinically important in all subgroups (15.7%, 20.3%, and 26.4%) after expanding the analysis to include grade 2 adverse events. Greater Q-TWiST gains were observed with nivolumab plus chemotherapy across most subgroups in all randomized patients and patients with PD-L1 CPS ≥ 1 and across all subgroups in patients with PD-L1 CPS ≥ 5.</p><p><strong>Conclusion: </strong>Clearly clinically important benefit in quality-adjusted survival with first-line nivolumab plus chemotherapy versus chemotherapy was observed across all evaluated PD-L1 CPS expression levels in patients with advanced GC/GEJC/EAC from CheckMate 649 with 4-year minimum follow-up.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT02872116.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"935-944"},"PeriodicalIF":5.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.","authors":"Zhenggang Zhu, Joji Kitayama, Hyung-Ho Kim, Jimmy Bok-Yan So, Hui Cao, Lin Chen, Xiangdong Cheng, Jiankun Hu, Motohiro Imano, Hironori Ishigami, Ye Seob Jee, Jong-Han Kim, Yasuhiro Kodera, Han Liang, Xiaowen Liu, Sheng Lu, Yiping Mou, Mingming Nie, Won Jun Seo, Yanong Wang, Dan Wu, Zekuan Xu, Hironori Yamaguchi, Chao Yan, Zhongyin Yang, Kai Yin, Yutaka Yonemura, Wei-Peng Yong, Jiren Yu, Jun Zhang","doi":"10.1007/s10120-025-01631-9","DOIUrl":"10.1007/s10120-025-01631-9","url":null,"abstract":"<p><p>Peritoneal metastasis (PM) is a major challenge in advanced gastric cancer (GC) with poor prognosis. Normothermic intraperitoneal and systemic treatment (NIPS) has become a promising therapeutic approach. This consensus aims to provide practical recommendations for NIPS treatment for gastric cancer with peritoneal metastasis (GCPM). The GRADE standards were used to rank evidence, and the Delphi method was employed for expert voting. 30 experts from China, Japan, South Korea, and Singapore participated in the development of this consensus. 28 experts participated in the voting process, which produced 29 statements covering diagnostic approaches, patient selection criteria, treatment regimens, management of intraperitoneal port placement, and conversion surgery considerations, and post-surgical treatment strategies in NIPS therapy. Based on current evidence and expert experience, these statements aim to improve the clinical outcomes of NIPS therapy for GCPM patients.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"731-748"},"PeriodicalIF":5.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}